Bosentan

Not Applicable

02/09/2024 Endothelin receptor antagonists for treating pulmonary arterial hypertension

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ambrisentan 5 mg and 10 mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:

  • Idiopathic PAH;

  • Heritable or familial PAH;

  • PAH associated with connective tissue disease;

  • Anorexigen-induced PAH; or

  • PAH associated with HIV infection.

Subsidy status

[R] Ambrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

[NR] MAF assistance does not apply to bosentan 62.5 mg and 125 mg tablets, and macitentan 10 mg tablet.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration